Search Results 891-900 of 17262 for monoclonal antibody

1. Tumor Shrinking Nanoparticle used to Fight Cancer and Brain Tumors - Mayo Clinic

   Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.

2. Publications - Madiha Fida, M.B.B.S. - Mayo Clinic

   ... monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023; 9 (2):veac104 Epub 2022 Nov 05. View PubMed ...

3. A Study of Pembrolizumab Alone as Therapy for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1; Prior chemotherapy, targeted ...

4. A Study to Assess the Effectiveness, Safety and Tolerability of Lu AF82422 in Patients with Multiple System Atrophy - Mayo Clinic

   - The participant has been treated with an anti-?-synuclein monoclonal antibody, mesenchymal stem cells or an inhibitor of ?-synuclein aggregation within ...

5. A Phase 1/​2 Study of STP938 for Adult Subjects With Relapsed/​Refractory B-Cell and T-Cell Lymphomas - Mayo Clinic

   study drug. - Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or <5 half ...

6. Stopping Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients - Mayo Clinic

   Other Monoclonal Antibodies: Subjects who have received any monoclonal antibody (other than XOLAIR®) to treat inflammatory disease within 5 half-lives of Visit ...

7. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   ... monoclonal antibodies. Patients must not have received prior treatment with a VEGFR tyrosine kinase inhibitor. Except for Cohort D (MSS mCRC), patients must ...

8. Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM - Mayo Clinic

   Active secondary malignancy; Prior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug, or not recovered from adverse effects ...

9. Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors - Mayo Clinic

   ... monoclonal antibodies; 1 week for hormonal anti-cancer therapy) prior to starting study drug or who have not recovered to grade 1 or better from related ...

10. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - Mayo Clinic

    ... monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone \[D-VTd\] and daratumumab + bortezomib/ lenalidomide/dexamethasone \[D-VRd\]), or ...